Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhou, Yao Yao ^a   Zhu, Gui Qi ^b,c   Liu, Tian ^a   Zheng, Ji Na ^b,c   Cheng, Zhang ^b,c   Zou, Tian Tian ^b,c   Braddock, Martin ^d   Fu, Shen Wen ^a   Zheng, Ming Hua ^b,c  

^a Jinhua Municipal Hospital   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN;

CHEMICALLY INDUCED; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; META ANALYSIS; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIVER NEOPLASMS; MALE; METFORMIN; RISK FACTORS;

EID: 84988535480     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep33743     Document Type: Review

References (47)

1. El-Serag, H. B. Hepatocellular carcinoma. The New England journal of medicine 365, 1118-1127, doi: 10.1056/NEJMra1001683 (2011).
2. Davila, J. A., Morgan, R. O., Shaib, Y., McGlynn, K. A. & El-Serag, H. B. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54, 533-539, doi: 10.1136/gut.2004.052167 (2005).
3. El-Serag, H. B., Tran, T. & Everhart, J. E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126, 460-468 (2004).
4. Nicolucci, A. Epidemiological aspects of neoplasms in diabetes. Acta diabetologica 47, 87-95, doi: 10.1007/s00592-010-0187-3 (2010).
5. Oberaigner, W. et al. Increased cancer incidence risk in type 2 diabetes mellitus: results from a cohort study in Tyrol/Austria. BMC public health 14, 1058, doi: 10.1186/1471-2458-14-1058 (2014).
6. Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J. & Thun, M. J. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. American journal of epidemiology 159, 1160-1167, doi: 10.1093/aje/kwh161 (2004).
7. Inoue, M. et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Archives of internal medicine 166, 1871-1877, doi: 10.1001/archinte.166.17.1871 (2006).
8. El-Serag, H. B., Hampel, H. & Javadi, F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 4, 369-380, doi: 10.1016/j.cgh.2005.12.007 (2006).
9. Donadon, V., Balbi, M., Casarin, P., Vario, A. & Alberti, A. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. World journal of gastroenterology 14, 5695-5700 (2008).
10. Donadon, V. et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World journal of gastroenterology 15, 2506-2511 (2009).
11. Lai, S. W. et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. The American journal of gastroenterology 107, 46-52, doi: 10.1038/ajg.2011.384 (2012).
12. Bosetti, C. et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. The oncologist 18, 148-156, doi: 10.1634/theoncologist.2012-0302 (2013).
13. Bowker, S. L., Majumdar, S. R., Veugelers, P. & Johnson, J. A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes care 29, 254-258 (2006).
14. Chen, H. P. et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62, 606-615, doi: 10.1136/gutjnl-2011-301708 (2013).
15. Donadon, V., Balbi, M., Mas, M. D., Casarin, P. & Zanette, G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver international: official journal of the International Association for the Study of the Liver 30, 750-758, doi: 10.1111/j.1478-3231.2010.02223.x (2010).
16. Chang, C. H. et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 55, 1462-1472, doi: 10.1002/hep.25509 (2012).
17. Home, P. D. et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53, 1838-1845, doi: 10.1007/s00125-010-1804-y (2010).
18. Yu, M. C., Tong, M. J., Govindarajan, S. & Henderson, B. E. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. Journal of the National Cancer Institute 83, 1820-1826 (1991).
19. Oliveria, S. A., Koro, C. E., Yood, M. U. & Sowell, M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2, 47-57 (2008).
20. Hassan, M. M. et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116, 1938-1946, doi: 10.1002/cncr.24982 (2010).
21. Kawaguchi, T. et al. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver international: official journal of the International Association for the Study of the Liver 30, 479-486, doi: 10.1111/j.1478-3231.2009.02191.x (2010).
22. Nkontchou, G. et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. The Journal of clinical endocrinology and metabolism 96, 2601-2608, doi: 10.1210/jc.2010-2415 (2011).
23. Ruiter, R. et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes care 35, 119-124, doi: 10.2337/dc11-0857 (2012).
24. Schlesinger, S. et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 24, 2449-2455, doi: 10.1093/annonc/mdt204 (2013).
25. Hagberg, K. W., McGlynn, K. A., Sahasrabuddhe, V. V. & Jick, S. Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes. British journal of cancer 111, 1710-1717, doi: 10.1038/bjc.2014.447 (2014).
26. Bosetti, C. et al. Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases. Pharmacoepidemiology and drug safety 24, 771-778, doi: 10.1002/pds.3801 (2015).
27. Miele, L. et al. Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk. Gastroenterology research and practice 2015, 570356, doi: 10.1155/2015/570356 (2015).
28. Chang, C. H., Lin, J. W., Wu, L. C., Lai, M. S. & Chuang, L. M. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. The Journal of clinical endocrinology and metabolism 97, E1170-E1175, doi: 10.1210/jc.2012-1162 (2012).
29. Singh, S., Singh, P. P., Singh, A. G., Murad, M. H. & Sanchez, W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. The American journal of gastroenterology 108, 881-891, quiz 892, doi: 10.1038/ajg.2013.5 (2013).
30. Decensi, A. et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer prevention research 3, 1451-1461, doi: 10.1158/1940-6207.CAPR-10-0157 (2010).
31. Harris, K. & Smith, L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. The Annals of pharmacotherapy 47, 1348-1352, doi: 10.1177/1060028013503108 (2013).
32. Zhang, H., Gao, C., Fang, L., Zhao, H. C. & Yao, S. K. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scandinavian journal of gastroenterology 48, 78-87, doi: 10.3109/00365521.2012.719926 (2013).
33. Franciosi, M. et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PloS one 8, e71583, doi: 10.1371/journal.pone.0071583 (2013).
34. Landman, G. W. et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes care 33, 322-326, doi: 10.2337/dc09-1380 (2010).
35. Pasello, G., Urso, L., Conte, P. & Favaretto, A. Effects of sulfonylureas on tumor growth: a review of the literature. The oncologist 18, 1118-1125, doi: 10.1634/theoncologist.2013-0177 (2013).
36. Belfiore, A., Frasca, F., Pandini, G., Sciacca, L. & Vigneri, R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocrine reviews 30, 586-623, doi: 10.1210/er.2008-0047 (2009).
37. Pollak, M. N., Schernhammer, E. S. & Hankinson, S. E. Insulin-like growth factors and neoplasia. Nature reviews. Cancer 4, 505-518, doi: 10.1038/nrc1387 (2004).
38. Moore, M. A., Park, C. B. & Tsuda, H. Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation 7, 89-107 (1998).
39. Jalving, M. et al. Metformin: taking away the candy for cancer? European journal of cancer 46, 2369-2380, doi: 10.1016/j. ejca.2010.06.012 (2010).
40. Gallagher, E. J. & Le Roith, D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Annals of the New York Academy of Sciences 1243, 54-68, doi: 10.1111/j.1749-6632.2011.06285.x (2011).
41. Bailey, C. J. & Turner, R. C. Metformin. The New England journal of medicine 334, 574-579, doi: 10.1056/NEJM199602293340906 (1996).
42. Dowling, R. J., Goodwin, P. J. & Stambolic, V. Understanding the benefit of metformin use in cancer treatment. BMC medicine 9, 33, doi: 10.1186/1741-7015-9-33 (2011).
43. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. The Journal of clinical investigation 108, 1167-1174, doi: 10.1172/JCI13505 (2001).
44. Okumura, T. Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. Journal of gastroenterology 45, 1097-1102, doi: 10.1007/s00535-010-0310-9 (2010).
45. Wu C. W., Farrell G. C. & Yu J. Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma. Journal of gastroenterology and hepatology 27, 1665-1669, doi: 10.1111/j.1440-1746.2012.07213.x (2012).
46. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of clinical epidemiology 62, 1006-1012, doi: 10.1016/j.jclinepi.2009.06.005 (2009).
47. Lumley T. Network meta-analysis for indirect treatment comparisons. Statistics in medicine 21, 2313-2324, doi: 10.1002/sim.1201 (2002).